Report cover image

Asia Pacific Human Microbiome Market Report (2021-2031) by Scope, Segmentation, Dynamics, and Competitive Analysis

Publisher The Insight Partners
Published Sep 01, 2025
Length 138 Pages
SKU # TIP20577447

Description

The Asia Pacific human microbiome market is projected to grow significantly, reaching approximately US$ 703.84 million by 2031, up from US$ 124.10 million in 2023, reflecting a robust compound annual growth rate (CAGR) of 24.2% during this period.

Executive Summary and Market Analysis

The market is divided into several regions, including Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. Key drivers of growth in this market include the rising prevalence of metabolic disorders, an increasing demand for research in gene mutation and drug development, and strategic collaborations among market participants. Additionally, government initiatives and funding aimed at enhancing awareness of the human microbiome are further propelling market expansion.

Market Segmentation

The Asia Pacific human microbiome market can be analyzed through various segments, including type, application, and disease type.
Type: The market is categorized into products and software/services, with the product segment dominating in 2023. This segment is further divided into probiotics and prebiotics.
Application: The market is segmented into therapeutics, diagnostics, and research, with therapeutics holding the largest market share in 2023.
Disease Type: The market is also segmented by disease type, including obesity, diabetes, autoimmune disorders, cancer, gastrointestinal (GIT) issues, and others, with the GIT segment leading in market share in 2023.

Market Outlook

The human microbiome's potential to revolutionize healthcare has led to a surge in investments in research and development. The microbiome, consisting of trillions of microorganisms residing in and on the human body, plays a crucial role in maintaining health and preventing diseases. Biotech startups and pharmaceutical companies are increasingly funding the development of microbiome-based therapies. For instance, Xome Life Sciences, one of India's pioneering microbiome startups, is focused on creating diagnostic and therapeutic tools that leverage microbiome data to enhance health outcomes.

Moreover, Seres Therapeutics has received FDA approval for a treatment targeting recurrent Clostridium difficile infections, showcasing the therapeutic potential of microbiome-based drugs. Companies like Vedanta Biosciences are also raising significant funds to develop immunotherapies derived from microbiomes for conditions such as autoimmune disorders and cancer. Notable investors, including Seventure Partners and Flagship Pioneering, are actively supporting companies that analyze microbiome data, highlighting the growing recognition of the microbiome's importance in health. This influx of investment is expected to drive advancements in precision medicine and therapeutic interventions, creating numerous opportunities within the market.

Country Insights

The Asia Pacific human microbiome market includes key countries such as China, Japan, India, Australia, South Korea, and others, with China holding the largest market share in 2023. Factors such as new pharmaceutical developments, product enhancements, and strategic partnerships are significantly benefiting the microbiome therapies market in China. For example, Xbiome Inc., an AI-driven microbiome therapeutics company, has acquired a clinical-stage program from Assembly Biosciences, which is focused on innovative treatments for viral disorders like hepatitis B.

The increasing prevalence of target disorders is expected to further stimulate growth in the human microbiome market. Research continues to uncover the microbiome's critical role in various health conditions, leading to a heightened interest in microbiome-based therapies, particularly for gastrointestinal disorders, autoimmune diseases, and metabolic disorders. The potential for microbiome therapeutics to offer more effective and personalized treatment options presents a promising avenue for market growth. According to the National Institute of Health, the prevalence of Irritable Bowel Syndrome (IBS) in China ranges from 2.3% to 15.8%, indicating a significant market opportunity.

Company Profiles

Key players in the human microbiome market include MaaT Pharma, Ferring Holdings SA, AOBiome Therapeutics Inc, Finch Therapeutics Group Inc, Seres Therapeutics Inc, Merck & Co Inc, Rebiotix, Inc., Yakult Honsha Co., Ltd., IFF Nutrition & Biosciences, and Synthetic Biologics, Inc. These companies are employing various strategies, including expansion, product innovation, and mergers and acquisitions, to enhance their product offerings and increase market share.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific human microbiome market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific human microbiome market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the Asia Pacific human microbiome market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution.

Table of Contents

138 Pages
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
3.2.1 Hypothesis formulation:
3.2.2 Macroeconomic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country-level data:
4. Asia Pacific Human Microbiome Market – Key Market Dynamics
4.1 Market Drivers
4.1.1 Significant Investments by Key Market Players
4.1.2 Government Initiatives
4.2 Market Restraints
4.2.1 Challenges During Production of Microbiome
4.3 Market Opportunities
4.3.1 Robust Investment in Research and Development
4.4 Future Trends
4.4.1 Emergence of Precision Medicine
4.5 Impact of Drivers and Restraints:
5. Human Microbiome Market – Asia Pacific Analysis
5.1 Asia Pacific Human Microbiome Market Revenue (US$ Million), 2021–2031
5.2 Asia Pacific Human Microbiome Market Forecast Analysis
6. Asia Pacific Human Microbiome Market Analysis – by Type
6.1 Product
6.1.1 Overview
6.1.2 Product: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
6.2 Software and Services
6.2.1 Overview
6.2.2 Software and Services: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
7. Asia Pacific Human Microbiome Market Analysis – by Application
7.1 Therapeutics
7.1.1 Overview
7.1.2 Therapeutics: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.2 Diagnostics
7.2.1 Overview
7.2.2 Diagnostics: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
7.3 Research
7.3.1 Overview
7.3.2 Research: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8. Asia Pacific Human Microbiome Market Analysis – by Disease Type
8.1 Obesity
8.1.1 Overview
8.1.2 Obesity: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.2 Diabetes
8.2.1 Overview
8.2.2 Diabetes: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.3 Autoimmune Disorder
8.3.1 Overview
8.3.2 Autoimmune Disorder: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.4 Cancer
8.4.1 Overview
8.4.2 Cancer: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.5 GIT
8.5.1 Overview
8.5.2 GIT: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
8.6 Others
8.6.1 Overview
8.6.2 Others: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9. Asia Pacific Human Microbiome Market – Country Analysis
9.1 Asia Pacific
9.1.1 Asia Pacific Human Microbiome Market Overview
9.1.2 Asia Pacific Human Microbiome Market – Revenue and Forecast Analysis – by Country
9.1.2.1 Asia Pacific Human Microbiome Market – Revenue and Forecast Analysis – by Country
9.1.2.2 China: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.1.2.2.1 China: Asia Pacific Human Microbiome Market Share – by Type
9.1.2.2.2 China: Asia Pacific Human Microbiome Market Share – by Product
9.1.2.2.3 China: Asia Pacific Human Microbiome Market Share – by Application
9.1.2.2.4 China: Asia Pacific Human Microbiome Market Share – by Disease Type
9.1.2.3 Japan: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.1.2.3.1 Japan: Asia Pacific Human Microbiome Market Share – by Type
9.1.2.3.2 Japan: Asia Pacific Human Microbiome Market Share – by Product
9.1.2.3.3 Japan: Asia Pacific Human Microbiome Market Share – by Application
9.1.2.3.4 Japan: Asia Pacific Human Microbiome Market Share – by Disease Type
9.1.2.4 India: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.1.2.4.1 India: Asia Pacific Human Microbiome Market Share – by Type
9.1.2.4.2 India: Asia Pacific Human Microbiome Market Share – by Product
9.1.2.4.3 India: Asia Pacific Human Microbiome Market Share – by Application
9.1.2.4.4 India: Asia Pacific Human Microbiome Market Share – by Disease Type
9.1.2.5 Australia: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.1.2.5.1 Australia: Asia Pacific Human Microbiome Market Share – by Type
9.1.2.5.2 Australia: Asia Pacific Human Microbiome Market Share – by Product
9.1.2.5.3 Australia: Asia Pacific Human Microbiome Market Share – by Application
9.1.2.5.4 Australia: Asia Pacific Human Microbiome Market Share – by Disease Type
9.1.2.6 South Korea: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.1.2.6.1 South Korea: Asia Pacific Human Microbiome Market Share – by Type
9.1.2.6.2 South Korea: Asia Pacific Human Microbiome Market Share – by Product
9.1.2.6.3 South Korea: Asia Pacific Human Microbiome Market Share – by Application
9.1.2.6.4 South Korea: Asia Pacific Human Microbiome Market Share – by Disease Type
9.1.2.7 Rest of APAC: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
9.1.2.7.1 Rest of APAC: Asia Pacific Human Microbiome Market Share – by Type
9.1.2.7.2 Rest of APAC: Asia Pacific Human Microbiome Market Share – by Product
9.1.2.7.3 Rest of APAC: Asia Pacific Human Microbiome Market Share – by Application
9.1.2.7.4 Rest of APAC: Asia Pacific Human Microbiome Market Share – by Disease Type
10. Industry Landscape
10.1 Overview
10.2 Growth Strategies in the Human Microbiome Market
10.3 Organic Growth Strategies
10.3.1 Overview
10.4 Inorganic Growth Strategies
10.4.1 Overview
11. Company Profiles
11.1 MaaT Pharma
11.1.1 Key Facts
11.1.2 Business Description
11.1.3 Products and Services
11.1.4 Financial Overview
11.1.5 SWOT Analysis
11.1.6 Key Developments
11.2 Ferring Holdings SA
11.2.1 Key Facts
11.2.2 Business Description
11.2.3 Products and Services
11.2.4 Financial Overview
11.2.5 SWOT Analysis
11.2.6 Key Developments
11.3 AOBiome Therapeutics Inc
11.3.1 Key Facts
11.3.2 Business Description
11.3.3 Products and Services
11.3.4 Financial Overview
11.3.5 SWOT Analysis
11.3.6 Key Developments
11.4 Finch Therapeutics Group Inc
11.4.1 Key Facts
11.4.2 Business Description
11.4.3 Financial Overview
11.4.4 SWOT Analysis
11.4.5 Key Developments
11.5 Seres Therapeutics Inc
11.5.1 Key Facts
11.5.2 Business Description
11.5.3 Products and Services
11.5.4 Financial Overview
11.5.5 SWOT Analysis
11.5.6 Key Developments
11.6 Merck & Co Inc
11.6.1 Key Facts
11.6.2 Business Description
11.6.3 Products and Services
11.6.4 Financial Overview
11.6.5 SWOT Analysis
11.6.6 Key Developments
11.7 Yakult Honsha Co., Ltd.
11.7.1 Key Facts
11.7.2 Business Description
11.7.3 Products and Services
11.7.4 Financial Overview
11.7.5 SWOT Analysis
11.7.6 Key Developments
11.8 Rebiotix, Inc.
11.8.1 Key Facts
11.8.2 Business Description
11.8.3 Products and Services
11.8.4 Financial Overview
11.8.5 SWOT Analysis
11.8.6 Key Developments
11.9 IFF Nutrition & Biosciences
11.9.1 Key Facts
11.9.2 Business Description
11.9.3 Products and Services
11.9.4 Financial Overview
11.9.5 SWOT Analysis
11.9.6 Key Developments
11.10 Synthetic Biologics, Inc.
11.10.1 Key Facts
11.10.2 Business Description
11.10.3 Products and Services
11.10.4 Financial Overview
11.10.5 SWOT Analysis
11.10.6 Key Developments
12. Appendix
12.1 Glossary of Terms
12.2 About The Insight Partners
List of Tables
Table 1. Asia Pacific Human Microbiome Market Segmentation
Table 2. Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Table 3. Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Type
Table 4. Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Application
Table 5. Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Disease Type
Table 6. Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million) – by Country
Table 7. China: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 8. China: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 9. China: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 10. China: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 11. Japan: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 12. Japan: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 13. Japan: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 14. Japan: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 15. India: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 16. India: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 17. India: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 18. India: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 19. Australia: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 20. Australia: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 21. Australia: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 22. Australia: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 23. South Korea: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 24. South Korea: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 25. South Korea: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 26. South Korea: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 27. Rest of APAC: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Type
Table 28. Rest of APAC: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Product
Table 29. Rest of APAC: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Application
Table 30. Rest of APAC: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021 – 2031 (US$ Million) – by Disease Type
Table 31. Recent Organic Growth Strategies in the Human Microbiome Market
Table 32. Recent Inorganic Growth Strategies in the Human Microbiome Market
Table 33. Glossary of Terms, Human Microbiome Market
List of Figures
Figure 1. Asia Pacific Human Microbiome Market Segmentation – Country
Figure 2. Asia Pacific Human Microbiome Market – Key Market Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Human Microbiome Market Revenue (US$ Million), 2021–2031
Figure 5. Asia Pacific Human Microbiome Market Share (%) – by Type (2023 and 2031)
Figure 6. Product: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 7. Software and Services: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 8. Asia Pacific Human Microbiome Market Share (%) – by Application (2023 and 2031)
Figure 9. Therapeutics: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 10. Diagnostics: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 11. Research: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 12. Asia Pacific Human Microbiome Market Share (%) – by Disease Type (2023 and 2031)
Figure 13. Obesity: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 14. Diabetes: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 15. Autoimmune Disorder: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 16. Cancer: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 17. GIT: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 18. Others: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021–2031 (US$ Million)
Figure 19. Asia Pacific Human Microbiome Market Breakdown, by Key Countries, 2023 and 2031 (%)
Figure 20. China: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 21. Japan: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 22. India: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 23. Australia: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 24. South Korea: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 25. Rest of APAC: Asia Pacific Human Microbiome Market – Revenue and Forecast, 2021– 2031 (US$ Million)
Figure 26. Growth Strategies in the Human Microbiome Market

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us